GSK plc (GSK) DCF calculator — discounted cash flow analysis
More analysis & context
More analysis tools
GSK on StockSpill
Other popular DCF models
GSK DCF calculator FAQ
- How do I run a DCF on a specific stock?
- Open any ticker’s analysis page to load financial statements, pre-filled free cash flow, and a scenario-based DCF model. Adjust growth rates, discount rate, and terminal multiple for bull, bear, and base cases.
- Is this DCF calculator free?
- Yes. The DCF model and financial statement viewer are free. Logged-in users can also save assumptions and weighted intrinsic value estimates per ticker.
- What data is used for GSK free cash flow?
- When available, GSK plc free cash flow is pre-filled from the latest cash flow statement as operating cash flow minus capital expenditures. You can override the starting FCF and any projected year manually.
- Can I compare GSK intrinsic value to its current price?
- The weighted scenario enterprise value is compared to the company’s market capitalization at calculation time, showing implied upside or downside versus the current market price.
How to value GSK plc (GSK) with a DCF model
This page combines GSK plc financial statements with a scenario-based discounted cash flow (DCF) calculator. Free cash flow is pre-filled from the latest cash flow statement when available — operating cash flow minus capital expenditures — and you can override any assumption.
Run normal, bull, and bear cases with different growth rates, discount rates, terminal multiples, and probability weights. The weighted enterprise value is compared to GSK's current market capitalization so you can estimate implied upside or downside.
Pair this DCF work with StockSpill smart-money data: see which superinvestors hold GSK, whether members of Congress have traded it recently, and whether insiders are buying or selling alongside your valuation view.
Key takeaways
- GSK income statement, balance sheet, and cash flows on one page.
- Save DCF assumptions and revisit weighted intrinsic value later.
- Cross-reference valuation with superinvestor, politician, and insider positioning.